Turkish Journal of Medical Sciences
Volume 35

Number 5

Article 8

1-1-2005

Prospective Analysis of Antibiotic Susceptibility Patterns of MRSA
in a Turkish University Hospital
LÜTFÜ SAVAŞ
NİZAMİ DURAN
YUSUF ÖNLEN
NAZAN SAVAŞ
MUSTAFA ERAYMAN

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
SAVAŞ, LÜTFÜ; DURAN, NİZAMİ; ÖNLEN, YUSUF; SAVAŞ, NAZAN; and ERAYMAN, MUSTAFA (2005)
"Prospective Analysis of Antibiotic Susceptibility Patterns of MRSA in a Turkish University Hospital,"
Turkish Journal of Medical Sciences: Vol. 35: No. 5, Article 8. Available at: https://journals.tubitak.gov.tr/
medical/vol35/iss5/8

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turk J Med Sci
35 (2005) 323-327
© TÜB‹TAK

CLINICAL INVESTIGATION

Prospective Analysis of Antibiotic Susceptibility Patterns of
MRSA in a Turkish University Hospital

Lütfü SAVAfi1, Nizami DURAN2*, Yusuf ÖNLEN1, Nazan SAVAfi3, Mustafa ERAYMAN4
1

Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Mustafa Kemal University, Hatay - Turkey

4

2

Department of Microbiology, Faculty of Medicine, Mustafa Kemal University, Hatay - Turkey

3

Department of Public Health, Medico Social Unit, Mustafa Kemal University, Hatay - Turkey

Department of Crop Science, Faculty of Agricultural, Mustafa Kemal University, Hatay - Turkey

Received: March 07, 2005

Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) is an important nosocomial pathogen. The prevalence of MRSA in
many countries is increasing and, in some hospitals, more than half of all S. aureus disease isolates are MRSA. MRSA strains are
becoming increasingly multiresistant, and have recently developed resistance to vancomycin, which has been used successfully to treat
MRSA for more than 30 years. In-vitro determination of resistance patterns of S. aureus is critical in terms of administering suitable
antimicrobial treatments. The objective of this study was to identify the frequency of MRSA from various clinical samples and
resistance patterns against various antibiotics used broadly for treatments. All isolated S. aureus strains were identified using
standard procedures and tested for oxacillin resistance according to methods of the National Committee for Clinical Laboratory
Standards. A total of 345 coagulase-positive Staphylococci and 187 MRSA were isolated. We found that the incidence of MRSA in
intensive care units (ICUs) and burn center was 23.4% (145/620) and 29.6% (32/108), respectively. This rate was 7% (10/143)
in the other units. Resistance rates of MRSA were 29.9% for trimethoprim-sulfamethoxazole, 60.8% for clindamycin, 71.8% for
erythromycin, 7.7% for teikoplanin, 90.1% for gentamycin, 88.8% for ofloxacin, 88.1% for norfloxacin and 100% for penicillin.
All isolates were found to be sensitive against vancomycin. In our region, although methicillin resistance increased in S. aureus
strains, teicoplanin resistance remained low in MRSA, suggesting an effective alternative treatment for Staphylococcus aureus
infections. These results indicated that vancomycin seemed to be the only antimicrobial agent effective against MRSA and it could be
the choice of medicine in treating multidrug resistant MRSA infection.
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Introduction

Staphylococcus aureus is recognized as one of the
most important bacterial pathogens seriously
contributing to the problem of hospital infections in
Turkey as well as world wide. Since the first isolation of
methicillin-resistant S. aureus (MRSA) in the United
Kingdom in 1961, increasing rates of methicillin
resistance among S. aureus strains have been a cause for
concern (1). MRSA is a major nosocomial pathogen that
causes severe morbidity and mortality worldwide (2).
MRSA strains spread more readily than others once
introduced into hospitals, and are often difficult to
eradicate once established. Presently in some countries
they can constitute up to 80% of all S. aureus isolates in

hospitals (3,4). Transmission of MRSA occurs primarily
from colonized or infected patients to other patients or
staff, or vice versa5. Among the resistant pathogens,
MRSA is of great concern because of the predominance of
this organism that causes various clinical infections (5,6).
Antimicrobial drug resistance has become a great
public health problem worldwide (7-9). As MRSA
incidences increased, the efficiency of penicillins and
sephalosporins has been questioned. Essentially, many
MRSA strains acquired resistance to both beta lactam and
aminoglycosides. Therefore, it is necessary to know the
MRSA prevalence and to choose suitable antibiotics with
respect to their antimicrobial profiles for treating the
infections (7-9).

323

Prospective Analysis of Antibiotic Susceptibility Patterns of MRSA in a Turkish University Hospital

Resistance to multiple antibiotics among the MRSA
isolates in hospitals has been recognized as one of the
major challenges in controlling hospital infections. The
pattern of bacterial resistance is important for
epidemiological and clinical purposes. The results of
antimicrobial resistance patterns are of great concern due
to the predominant bacterial isolates which are highly
resistant to the commonly available antimicrobial agents.
Recently, a marked increase in the number of hospital
infections caused by MRSA has been reported in many
countries (7-11).
It was reported that the percentage of MRSA ranged
from 29% to 35% of all clinical isolates in many
American and European hospitals. On the contrary,
information about the distribution of MRSA in the global
community appears to be tentative because majority of
data was obtained from developed countries while data
was imprecisely obtained from underdeveloped or
developing countries. Meanwhile, information from
developing countries was provided by relatively
sophisticated hospitals (11-13).
Continued collaborative efforts are required on
national, provincial and regional levels to control the
antibiotic resistance. The number of studies about the
prevalence of MRSA strains and their resistance patterns
against antibiotics was inadequate in Turkey as in many
other countries. The prevalence of MRSA was found to
differ tremendously among the cities of Turkey (7-9,12).
The present study was undertaken to ascertain the
relationship among MRSA strains isolated from various
clinical specimens in Baskent University Hospital, Adana,
Turkey. Our objective was to determine the percentage of
S. aureus among all nosocomial isolates and the
percentage of MRSA among these S. aureus isolates. In
addition, we investigated the resistance patterns of the
isolated MRSA strains for various antibiotics.

Materials and Methods
This study was performed to find the prevalence of
hospital-acquired MRSA infection from several
departments and intensive care units (ICUs) between
2001 and 2002 in Baskent University Hospital in Adana,
Turkey. In this study, the isolation rate of coagulase
positive Staphylococci was 39.6% (345/871) from
various clinical samples such as respiratory tract, blood,
urine, catheters, surgical wound.
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Bacterial strains
The present study involved a total of 345 consecutive
isolates of S. aureus collected from Baflkent University
Hospital. Numbers of clinical specimens and their rates
were as follows: surgical wounds (n = 90, 26.1%), urine
(n = 98, 28.4%), burns (n = 60, 17.4%), blood (n = 52,
15.1%), catheters (n = 30, 8.7%), and other sources (n
= 15, 4.3%). To isolate Staphylococci, samples were
inoculated onto sheep blood-agar plates and phenol-red
mannitol salt agar plates. The plates were incubated at 37
°C for 48 h. Identification of S. aureus was based upon
colony morphology, biochemical activities and coagulase
tests (6).
Identification of S. aureus was confirmed by standard
methods and susceptibility testing was performed by disc
diffusion on Mueller-Hinton agar (Difco, USA) with 24-h
incubation at 35 °C. Interpretation criteria were those of
the National Committee for Clinical Laboratory Standards
(NCCLS) (14). Resistance to oxacillin was confirmed by
the screen agar test. Oxacillin discs (1µg) were obtained
from the Oxoid firm (Oxoid, USA). Strains producing
inhibition less than 10 mm zone diameter or producing
no inhibition were considered resistant to oxacillin.
Susceptibility of isolated MRSA strains to penicillin (10
µg/disc), gentamycin (10 µg/disc), trimethoprimsulphamethoxazole (1.25/23.75 µg/disc) erythromycin
(15 µg/disc), clindamycin (2 µg/disc), teicoplanin (30
µg/disc), ofloxacin (5 µg/disc), norfloxacin (10 µg/disc),
and vancomycin (30 µg/disc) was tested. All antibiotic
discs were obtained from Oxoid. ATCC 25923 was used
as the control strain for identification and susceptibility
tests.

Statistical analysis
Statistical analysis was performed using a chi squared
test and P values less than 0.05 were considered
statistically significant. The statistical analyses were
performed by using Statistical Package for Social Sciences
(SPSS, ver. 10.0) software.

Findings
In this study, S. aureus was present in 39.6%
(345/871) of the samples taken from the clinics [18.1%
MRSA and 21.5% methicillin sensitive S. aureus (MSSA)].
They were isolated from the following clinical specimens:

L. SAVAfi, N. DURAN, Y. ÖNLEN, N. SAVAfi, M. ERAYMAN

burns (n = 60, 17.4%), surgical wounds (n = 90,
18.0%), urine (n = 98 28.4%), blood (n = 52, 15.1%),
catheters (n = 30, 8.7%), and and other sources (n = 15,
4.3%). The rate of MRSA was 54.2% (187/345) of
isolated S. aureus. While the isolation rate of S. aureus
was 69.9% (241/345) in ICUs and burn centers, it was
30.1% (104/345) in the other departments.
Figure 1 shows the departments from which MRSA
were isolated. The isolation rate was 27.4% (45/164) in
general surgical ICU, 17.8% (18/101) in burn centers
and 17.2% (31/180) in internal ICU, and these units
were followed by cardiovascular surgical ICU and
coronary ICU as 11.8% (22/187) and 7.5% (14/187),
respectively.
The most effective antibiotics against MRSA are
glycopeptide antibiotics and of 187 MRSA strains, no
resistance was acquired against vancomycin although
resistance
against
teicoplanin,
trimethoprimsulfamethoxazole and clindamycin were 7.7%, 29.9%,
60.8%, respectively. Resistance to norfloxacin and
oflaxacin from the quinolone group was 88.8% and
88.1%, respectively. All strains were resistant to
penicillin (resistance rate: 100%) and the resistance to
gentamycin and erythromycin were 71.8%, 90.1,
respectively (Figure 2).

Discussion
MRSA prevalence has been increasing from the first
day it was identified. Although it was rarely reported at

first, it has become most resistant not only to all betalactams but also to a wide range of other antibiotics, and
has emerged as the major nosocomial pathogens during
the past two decades. Furthermore, multi-drug resistant
MRSA has become a major problem (1,2,5,6).
Considerable variations in the prevalence of MRSA exist
among institutions and geographic areas. In Turkey,
there are a number of studies for comparing methiciline
and other antibiotic resistance of Staphylococci. Results
of these studies differed with respect to the research
centers (7-9,12).
Resistance to multiple antibiotics among the
Staphylococci isolates in hospitals has been recognized as
one of the major challenges in controlling hospital
infections. The pattern of bacterial resistance is important
for epidemiological and clinical purposes. The results of
the antimicrobial resistance pattern give serious cause for
concern because the predominant bacterial isolates were
highly resistant to the commonly available antimicrobial
agents. Recently, a substantial increase in the number of
hospital infections due to MRSA has been reported in
many countries (4,9-15,16-19). Although MRSA
prevalence was found between 16-59% in Turkey (79,12) this range is reported between 1-40% in Europe
(5,12) and 6-50% in the U.S.A. (15,20).
The proportion of MRSA in the various European
countries ranged from <1% in Scandinavia to >30% in
Spain, France and Italy. In Europe in general, a northsouth gradient is observed, MRSA strains being rare in
Scandinavian hospitals (<2%) and far more prevalent in
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Figure 1. Isolation percentages of MRSA strains according to departments.
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Figure 2. Resistance patterns of MRSA strains.

Mediterranean hospitals (>40%). Whether low or high,
the rates of MRSA prevalence in European countries have
remained approximately the same during the last decade.
Recent findings suggest that MRSA might also be
emerging as a community-acquired pathogen (4,5).
It was reported that the rates of resistance among
non-glycopeptide antibiotics were lowest for rifampin and
highest for ciprofloxacin, and MRSA was found more
frequently in intensive care patients (13,16). MRSA
seems to be a growing problem, especially in southern
Europe, where incidence and rates of antibiotic resistance
are alarmingly high (4,5,17).
MRSA is a pathogen of special concern in ICUs. The
burn units are especially a very susceptible niche for
colonization and infection events by this organism
(16,19).
In the present study, among the S. aureus isolated
from patients in the various departments, ICU and burn
centers, the general incidence of MRSA was noticeably
higher than those reported from other countries (16-18).
In our study, the incidence of MRSA was 23.4%
(145/620) in ICUs whereas it was17.8% (18/101) in
burn centers. While the MRSA rate in ICUs was 23.4%
(145/620), it was 16.7% (42/251) in burn centers and
the other department patients. There was a significant
difference between ICU patients and the others
department patients according to occurrence of MRSA
rate, (P<0.01).
The majority of MRSA is resistant to erythromycin,
clindamycin, gentamycin and quinolons (9-11). In this
study, we found that penicillin was not effective for
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MRSA strains. Penicillin resistance rate was identified as
100% and gentamycin resistance rate was 90.1%.
Resistance to quinolons was also quite high (88.1% for
norfloxin, 88.8% for ofloxacin).
The most active drugs against S. aureus are
vancomycin,
teikoplanin
and
trimethoprimsuplhamethoxazole (11). The incidence of MRSA resistant
to clindamycin (60.8%), erythromycin (71.8%),
norfloxacin (88.1%), gentamycin (90.1%) and penicillin
(100%) were very high.
Susceptibility to gentamycin from glycopeptide
antibiotics was found quite low (9.9%). Although
ofloxacin susceptibility was higher than that of other
quinolones (norfloxacin; 11.9%) it was not
recommended for empiric treatments of MRSA
infections.
Results about resistance rates found in Turkey were
in accordance with those in other parts of the world.
Susceptibility to glycopeptide antibiotics was found to be
maximum in gentamycin (9.9%), and lowest in
clindamycin (39.2%). Strains were also susceptible to
erythromycin 28.2%. The reason that we found higher
MRSA prevalence may be due to haphazard antibiotic
usage.
Vancomycin continues to be the drug of choice for
treating most MRSA infections caused by multidrug
resistant strains. In recent years, reports of the existence
of moderately susceptible isolates among MRSA strains in
many countries including the USA, Korea and Hong Kong
and of vancomycin resistant S. aureus strains in the USA
in 2002 makes it necessary to search for the resistance
patterns to vancomycin. In our study, all strains were
found to be susceptible to vancomycin (20-24).
Additionally, MRSA strains sampled from the ICUs and
various departments were found to have high resistance
to widely used antibiotics for treatments.
Vancomycin seemed to be the only antimicrobial agent
effective against MRSA and it could be the choice of
medicine in treating multidrug resistant MRSA infections.
However, vancomycin susceptibility should be regularly
inspected and routine tests should be done for new
glycopeptides such as teicoplanin. Furthermore,
regarding hospital-related infections, constant studies
monitoring antibiotic susceptibility patterns of MRSA
should be performed.
It was claimed that the rates of MRSA colonization
may vary in terms of both risk factors and geographical
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regions (17). In this study, it was found that, especially
intensive care patients were at great risk to MRSA
infection. Surveillance studies should be carried out in
every geographical region to detect the prevalence of
MRSA strains, and appropriate infection control measures
should be performed to prevent infection with
corresponding strains. In conclusion, considering the
increasing occurence of MRSA infections, highly reliable,
accurate, and rapid testing for methicillin resistance is
essential for both antibiotic therapy and infection control
regimens.
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